Logo

Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

Jan 17, 2005

NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.

 

Ambit will use its kinase platform to profile the specificity of certain compounds from GSK and Bristol-Myers. The platform consists of more than 170 quantitative, high-throughput kinase assays.

 

The company will also try to identify and characterize the protein targets of certain Pfizer compounds using its reverse screening technology that covers a large fraction of all human proteins.

 

Ambit has had previous collaborations with all three drug makers.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.